Dividend yield at 3.4% continues to attract income-focused investors, supporting a floor for ABBV stock price during market pullbacks. The firm forecasts that as pressure from Humira biosimilars decline, Abbvie’s total top-line growth will pick up speed, rising from 8% in 2025 to 11% in 2026. Though no specifics were given, Leerink also identified three oncology pipeline candidates that would eventually contribute significantly to Abbvie’s revenue. Why Options Traders Are Betting Big on Oracle Stock Analysts forecast ABBV stock price could test the $170 resistance level in the coming weeks, driven by strong earnings guidance and a diversified therapeutic portfolio.
